Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous BAFFR-targeting CAR T cells

A preparation of autologous T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) B-cell activating factor receptor (BAFFR; tumor necrosis factor receptor superfamily member 13C; TNFRSF13C; BLyS receptor 3; BR3), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous BAFFR-targeting CAR T cells are directed to and induce selective toxicity in BAFFR-expressing tumor cells. BAFFR, a protein belonging to the TNF receptor superfamily, is expressed on the surface of certain types of cancer cells, including B-cell acute lymphoblastic leukemia. It plays a key role in the regulation of peripheral B-cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous BAFFR-CAR T cells
autologous BAFFR-CAR-expressing T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search